- Home
- TRDA vs IMMP Comparison
TRDA vs IMMP Comparison
Compare TRDA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- IMMP
- Stock Information
- Founded
- TRDA 2016
- IMMP 1987
- Country
- TRDA United States
- IMMP Australia
- Employees
- TRDA N/A
- IMMP N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- TRDA Health Care
- IMMP Health Care
- Exchange
- TRDA Nasdaq
- IMMP Nasdaq
- Market Cap
- TRDA 301.0M
- IMMP 251.8M
- IPO Year
- TRDA 2021
- IMMP N/A
- Fundamental
- Price
- TRDA $7.12
- IMMP $1.60
- Analyst Decision
- TRDA Strong Buy
- IMMP Buy
- Analyst Count
- TRDA 3
- IMMP 1
- Target Price
- TRDA $25.67
- IMMP $7.00
- AVG Volume (30 Days)
- TRDA 126.5K
- IMMP 97.6K
- Earning Date
- TRDA 08-12-2025
- IMMP 02-27-2025
- Dividend Yield
- TRDA N/A
- IMMP N/A
- EPS Growth
- TRDA N/A
- IMMP N/A
- EPS
- TRDA 0.61
- IMMP N/A
- Revenue
- TRDA $172,220,000.00
- IMMP $3,019,249.00
- Revenue This Year
- TRDA N/A
- IMMP $50.37
- Revenue Next Year
- TRDA N/A
- IMMP N/A
- P/E Ratio
- TRDA $11.70
- IMMP N/A
- Revenue Growth
- TRDA 5.74
- IMMP 24.11
- 52 Week Low
- TRDA $6.94
- IMMP $1.32
- 52 Week High
- TRDA $21.79
- IMMP $2.80
- Technical
- Relative Strength Index (RSI)
- TRDA 36.18
- IMMP 34.41
- Support Level
- TRDA $6.94
- IMMP $1.81
- Resistance Level
- TRDA $8.49
- IMMP $1.92
- Average True Range (ATR)
- TRDA 0.42
- IMMP 0.08
- MACD
- TRDA -0.07
- IMMP -0.03
- Stochastic Oscillator
- TRDA 10.91
- IMMP 0.00
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.